Biotechnology & Medical Research

Protalix Biotherapeutics names Shlomo Yanai as Chairman

Protalix Biotherapeutics Inc:Says Shlomo Yanai has been appointed as the Chairman effective July 24.Says Zeev Bronfeld, the interim Chairman of the Board, will remain a member of the Board of Directors.

8:00am EDT

Celsion announces positive interim data update from its Phase 2 DIGNITY study in Breast Cancer

Celsion Corp:Says positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer.Trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia.

8:00am EDT

Lpath reports interim data from Phase 2a study for Anti-Cancer Drug, ASONEP

Lpath Inc:Reports interim results in a Phase 2a single-arm, open-label trial where ASONEP is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients.Lpath has enrolled 26 patients in the study.ASONEP has a favorable safety profile thus far, with no serious adverse...

8:00am EDT

Immune Design Corp announces pricing of initial public offering

Immune Design Corp:Prices its initial public offering of 5,000,000 shares of its common stock at a price of $12.00 per share for an aggregate offering of $60.0 mln, before underwriting discounts, commissions and expenses.Grants the underwriters a 30-day option to purchase up to 750,000 additional...

7:01am EDT

Expansion & New Markets

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.